Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients
NCT ID: NCT02238288
Last Updated: 2014-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
154 participants
INTERVENTIONAL
2013-12-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
NCT04662515
The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery
NCT06983886
Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
NCT05523297
Efficacy of Topical Versus Intravenous Tranexamic Acid in Controlling Blood Loss
NCT06188052
Effect of Perioperative Tranexamic Acid on Blood Loss During Management of Maxillofacial Trauma
NCT04494126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group 1 (EACA) - patients will receive the intra-alveolar application of a 500 mg tablet of the epsilon-amino caproic acid (EACA - Ipsilon® - Nikko Brazil, RJ) crushed in 0.9% saline. Additionally, they will be instructed to rinse with 500mg EACA tablets macerated and diluted in 2 tablespoons of water three times a day, in the two days after the extraction.
Group 2 (control) - patients will receive routine postoperative care.
Classification of Bleeding will be performed by the professional on the day of surgery at two times: one time (immediately after extraction) and time 2 (after 20 minutes). The bleeding will be classified as follows:
* No bleeding
* Light bleeding - blood in saliva
* Moderate Bleeding - bleeding controlled with local measures
* Severe Bleeding - when surgical intervention is required
Late bleeding will be recorded by the patient through daily questionnaire. The bleeding will be classified as follows:
* No bleeding
* Blood stained saliva
* Bleeding that stopped after compression bandage and ice pack for 20 minutes
* Bleeding stopped only after professional intervention
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
aminocaproic acid
Crushed tablets inserted in the dental socket post-extraction
Aminocaproic acid
Crushed tablet in the dental socket
lidocaine and epinephrine
2%
Paracetamol
750 mg
Routine care after dental extraction
Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
Routine dental care
Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
lidocaine and epinephrine
2%
Paracetamol
750 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aminocaproic acid
Crushed tablet in the dental socket
Routine dental care
Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
lidocaine and epinephrine
2%
Paracetamol
750 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
OTHER_GOV
Grupo de Estudos Multicentricos em Onco-Hematologia
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clementino Fraga Filho University Hospital
Rio de Janeiro, Rio de Janeiro, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AEAC2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.